VeriSIM Life

VeriSIM Life is an AI-powered drug discovery company offering a machine learning-driven platform, BIOiSIM, which allows pharmaceutical companies and drug developers to conduct preclinical experiments using biosimulation models that reflect interactions between drugs and animals' biological systems. The platform can predict a potential drug’s response and clinical outcome without the need for actual animal testing, thereby reducing the cost and time spent on animal trials or even entirely eliminating them.

The company is also engaged in developing novel therapeutics through its subsidiary PulmoSIM Therapeutics, which leverages the BIOiSIM platform. PulmoSIM has two drug candidates in its pipeline targeting pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), both of which are in their preclinical stages. VeriSIM Life acquired Spanish biotechnology firm Molomics Biotech in May 2022, to integrate VeriSIM’s platform with Molomics’ Human Collective Intelligence (HCI) technology, enhancing the company’s ability to make successful clinical trial predictions.

In April 2024, VeriSIM Life launched its AtlasGEN Novel Drug Designer, a platform that focuses on combining generative chemical discovery and biological validation to increase efficiency in drug candidate selection. It is part of the BIOiSIM platform that uses a unique Translational Index to give insights into the AI analysis and the potential effectiveness and safety of created compounds.